Climb Bio (CLYM) Receivables - Accured (2021 - 2025)

Climb Bio has reported Receivables - Accured for 5 years, with the latest figure at $1.3 million in Q1 2025.

• For the quarter ending Q1 2025, Receivables - Accured changed N/A year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2025 stood at $1.3 million (changed N/A YoY), and the FY2024 full-year result was $800000.0, up 81.82% from the prior year.
• Receivables - Accured for Q1 2025 stood at $1.3 million, up from $800000.0 in the prior quarter.
• The five-year high for Receivables - Accured was $1.3 million in Q1 2025, with the low at $100000.0 in Q4 2022.
• Historically, Receivables - Accured has averaged $440769.2 across 5 years, with a median of $300000.0 in 2021.
• Annual changes were most pronounced in 2022 — Receivables - Accured slumped 80.0% — and 2023, when it surged 340.0%.
• Climb Bio's Receivables - Accured stood at $500000.0 in 2021, then tumbled by 80.0% to $100000.0 in 2022, then soared by 340.0% to $440000.0 in 2023, then jumped by 81.82% to $800000.0 in 2024, then jumped by 62.5% to $1.3 million in 2025.
• The last three Receivables - Accured figures came in at $1.3 million (Q1 2025), $800000.0 (Q4 2024), and $990000.0 (Q3 2024), per Business Quant data.